gabapentin has been researched along with Recrudescence in 25 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 7.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| " First, the maximally effective gabapentin dosage (600-2,700 mg/day) for each patient was determined during an initial dose-titration phase." | 6.72 | Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006) |
| "Gabapentin monotherapy was useful and safe for late poststroke ES." | 6.70 | Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002) |
| "To report a case of recurrent hot flashes unresponsive to gabapentin in a postmenopausal patient with a positive family history of breast cancer." | 3.81 | Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer. ( Lake, J; Leong, C, 2015) |
| "Gabapentin is an antiepileptic medication that also has been used for restless legs syndrome." | 3.73 | Gabapentin-induced myopathy in 2 patients on short daily hemodialysis. ( Lavoie, S; Lipson, J; Zimmerman, D, 2005) |
| "A chart review was conducted on 27 outpatients presenting with a depressive disorder in whom gabapentin was added to ongoing treatment with a conventional antidepressant to which patients had not responded after at least 6 weeks." | 3.71 | Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review. ( Carpenter, LL; Leon, Z; Price, LH; Siniscalchi, JM; Yasmin, S, 2001) |
| "This report describes the results of maintenance treatment with gabapentin in 18 previously refractory Bipolar Disorder patients who initially responded to augmentation with gabapentin during the acute phase of their therapy." | 3.70 | Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment. ( Schaffer, CB; Schaffer, LC, 1999) |
| "Cocaine dependence is a major public health problem with no available robustly effective pharmacotherapy." | 2.79 | Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms. ( Cargile, C; Chopra, MP; Guise, JB; Kosten, TR; Mancino, MJ; McGaugh, J; Oliveto, A; Sanders, N; Thostenson, J; Williams, DK, 2014) |
| "Post-treatment, gabapentin-treated participants had less probability of drinking during the follow-up post-treatment period (p = 0." | 2.74 | A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. ( Anton, RF; Becker, HC; Boyle, E; Malcolm, R; Myrick, H; Randall, CL; Randall, PK, 2009) |
| " First, the maximally effective gabapentin dosage (600-2,700 mg/day) for each patient was determined during an initial dose-titration phase." | 2.72 | Blinded placebo crossover study of gabapentin in primary orthostatic tremor. ( Byrnes, ML; Edwards, DJ; Mastaglia, FL; Rodrigues, JP; Stell, R; Thickbroom, GW; Walters, SE, 2006) |
| "Gabapentin is an antiepileptic drug shown to be effective in the treatment of pain disorders and appears to be useful as well for several psychiatric disorders, including bipolar disorder, anxiety disorders, alcohol withdrawal and cocaine dependence." | 2.71 | Add-on gabapentin in the treatment of opiate withdrawal. ( Castellano, M; Cervera, G; Martínez-Raga, J; Perez-Galvez, B; Sabater, A, 2004) |
| "Gabapentin monotherapy was useful and safe for late poststroke ES." | 2.70 | Gabapentin in late-onset poststroke seizures. ( Alvarez-Sabín, J; Codina, A; Molina, CA; Montaner, J; Padró, L; Quintana, M; Rovira, R, 2002) |
| "The mainstay of migraine treatment is pharmacotherapy." | 2.42 | The role of anticonvulsants in preventive migraine therapy. ( Corbo, J, 2003) |
| "Although antiepileptic drugs (AEDs) are commonly used to control and prevent seizures, their long-term use carries a considerable risk of morbidity." | 2.41 | Antiepileptic drug therapy for adults: when to initiate and how to choose. ( Sirven, JI, 2002) |
| "Occipital neuralgia is a pain in the distribution of the occipital nerves, accompanied by hypersensitivity to touch in the corresponding territory." | 1.39 | [Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients]. ( Barón, J; Guerrero-Peral, ÁL; Herrero-Velázquez, S; Mulero, P; Muñoz, I; Pedraza, MI; Rodríguez, C; Ruiz, M, 2013) |
| "Sickle cell disease is a very common entity in central India, especially in Maharashtra." | 1.38 | Sickle cell disease with recurrent priapism. ( Aher, A; Khot, R, 2012) |
| "Gabapentin is a gamma-aminobutyric acid (GABA) analogue, with GABAmimetic pharmacological properties." | 1.35 | Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats. ( Ashby, CR; Gagare, PD; Gardner, EL; Li, J; Li, X; Peng, XQ; Pratihar, D; Ramachandran, PV; Xi, ZX, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.00) | 18.2507 |
| 2000's | 15 (60.00) | 29.6817 |
| 2010's | 7 (28.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zheng, C | 1 |
| Childers, J | 1 |
| Rabinovich, E | 1 |
| Nazareth-Pidgeon, K | 1 |
| Miao, J | 1 |
| Aboagye, DE | 1 |
| Chulpayev, B | 1 |
| Liu, L | 1 |
| Ishkanian, G | 1 |
| Kolanuvada, B | 1 |
| Alaie, D | 1 |
| Petrillo, RL | 1 |
| Kranzler, HR | 1 |
| Feinn, R | 1 |
| Morris, P | 1 |
| Hartwell, EE | 1 |
| Khot, R | 1 |
| Aher, A | 1 |
| Pedraza, MI | 1 |
| Ruiz, M | 1 |
| Rodríguez, C | 1 |
| Muñoz, I | 1 |
| Barón, J | 1 |
| Mulero, P | 1 |
| Herrero-Velázquez, S | 1 |
| Guerrero-Peral, ÁL | 1 |
| Mancino, MJ | 1 |
| McGaugh, J | 1 |
| Chopra, MP | 1 |
| Guise, JB | 1 |
| Cargile, C | 1 |
| Williams, DK | 1 |
| Thostenson, J | 1 |
| Kosten, TR | 1 |
| Sanders, N | 1 |
| Oliveto, A | 1 |
| Leong, C | 1 |
| Lake, J | 1 |
| Myrick, H | 2 |
| Malcolm, R | 1 |
| Randall, PK | 2 |
| Boyle, E | 1 |
| Anton, RF | 2 |
| Becker, HC | 1 |
| Randall, CL | 1 |
| Schacht, JP | 1 |
| Waid, LR | 1 |
| Baros, AM | 1 |
| Latham, PK | 1 |
| Wright, TM | 1 |
| Sirven, JI | 1 |
| Alvarez-Sabín, J | 1 |
| Montaner, J | 1 |
| Padró, L | 1 |
| Molina, CA | 1 |
| Rovira, R | 1 |
| Codina, A | 1 |
| Quintana, M | 1 |
| Corbo, J | 1 |
| Perimenis, P | 1 |
| Athanasopoulos, A | 1 |
| Papathanasopoulos, P | 1 |
| Barbalias, G | 1 |
| Martínez-Raga, J | 1 |
| Sabater, A | 1 |
| Perez-Galvez, B | 1 |
| Castellano, M | 1 |
| Cervera, G | 1 |
| Lipson, J | 1 |
| Lavoie, S | 1 |
| Zimmerman, D | 1 |
| Rodrigues, JP | 1 |
| Edwards, DJ | 1 |
| Walters, SE | 1 |
| Byrnes, ML | 1 |
| Thickbroom, GW | 1 |
| Stell, R | 1 |
| Mastaglia, FL | 1 |
| Petroianu, G | 1 |
| Stegmeier-Petroianu, A | 1 |
| Peng, XQ | 1 |
| Li, X | 1 |
| Li, J | 1 |
| Ramachandran, PV | 1 |
| Gagare, PD | 1 |
| Pratihar, D | 1 |
| Ashby, CR | 1 |
| Gardner, EL | 1 |
| Xi, ZX | 1 |
| Ackerman, WE | 1 |
| Ahmad, M | 1 |
| Haugen, RN | 1 |
| Tharp, MD | 1 |
| Corá-Locatelli, G | 1 |
| Greenberg, BD | 1 |
| Martin, JD | 1 |
| Murphy, DL | 1 |
| Schaffer, CB | 1 |
| Schaffer, LC | 1 |
| Wheeler, DS | 1 |
| Vaux, KK | 1 |
| Tam, DA | 1 |
| Yasmin, S | 1 |
| Carpenter, LL | 1 |
| Leon, Z | 1 |
| Siniscalchi, JM | 1 |
| Price, LH | 1 |
| Obrocea, GV | 1 |
| Dunn, RM | 1 |
| Frye, MA | 1 |
| Ketter, TA | 1 |
| Luckenbaugh, DA | 1 |
| Leverich, GS | 1 |
| Speer, AM | 1 |
| Osuch, EA | 1 |
| Jajodia, K | 1 |
| Post, RM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| A Double Blind Evaluation of Flumazenil and Gabapentin for the Treatment of Alcohol Withdrawal and Relapse Prevention[NCT00262639] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Neurocognitive and Neurobehavioral Mechanisms of Change Following Psychological[NCT03842670] | 140 participants (Anticipated) | Interventional | 2018-11-14 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
percent days abstinent during treatment (NCT00262639)
Timeframe: Weeks 1 to 6
| Intervention | percent days (Mean) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 70.8 |
| Low CIWAar Placebo | 86.1 |
| High CIWAar Placebo | 75.9 |
| High CIWAar Flumazenil/Gabapentin | 95.9 |
percent of subjects completely abstinent during the six week medication study study (NCT00262639)
Timeframe: 6 week trial
| Intervention | percent of participants (Number) |
|---|---|
| Low CIWA Flumazenil/Gabapentin | 44 |
| Low CIWAar Placebo | 19 |
| High CIWAar Placebo | 33 |
| High CIWAar Flumazenil/Gabapentin | 71 |
3 reviews available for gabapentin and Recrudescence
| Article | Year |
|---|---|
A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder.
Topics: Alcohol Abstinence; Alcoholism; Excitatory Amino Acid Antagonists; Gabapentin; Humans; Randomized Co | 2019 |
Antiepileptic drug therapy for adults: when to initiate and how to choose.
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Epilepsy; Felb | 2002 |
The role of anticonvulsants in preventive migraine therapy.
Topics: Acetates; Amines; Anticonvulsants; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Appro | 2003 |
8 trials available for gabapentin and Recrudescence
| Article | Year |
|---|---|
Clinical efficacy of sertraline alone and augmented with gabapentin in recently abstinent cocaine-dependent patients with depressive symptoms.
Topics: Adult; Amines; Cocaine-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; C | 2014 |
A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.
Topics: Adult; Alcohol Drinking; Amines; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Doub | 2009 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cognition; Cyclohexanecarboxylic Acids; Drug Therapy, C | 2011 |
Gabapentin in late-onset poststroke seizures.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Dr | 2002 |
Gabapentin in the management of the recurrent, refractory, idiopathic priapism.
Topics: Acetates; Adult; Amines; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Am | 2004 |
Add-on gabapentin in the treatment of opiate withdrawal.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Female; Gab | 2004 |
Blinded placebo crossover study of gabapentin in primary orthostatic tremor.
Topics: Aged; Amines; Antiparkinson Agents; Cross-Over Studies; Cyclohexanecarboxylic Acids; Dizziness; Doub | 2006 |
Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders.
Topics: Acetates; Adult; Aged; Amines; Antidepressive Agents; Cross-Over Studies; Cross-Sectional Studies; C | 2002 |
14 other studies available for gabapentin and Recrudescence
| Article | Year |
|---|---|
Recurrent Henoch-Schönlein Purpura with bullous rash and pulmonary nodules.
Topics: Biopsy, Fine-Needle; Bronchoalveolar Lavage Fluid; Chest Pain; Child; Complement C3; Cough; Female; | 2020 |
Importance of Regular and Maintenance Therapy Adherence in Neuromyelitis Optica (NMO): Lessons from a Repeating Relapse Case.
Topics: Amines; Analgesics; Autoantibodies; Biomarkers; Chronic Disease; Cyclohexanecarboxylic Acids; Female | 2018 |
Sickle cell disease with recurrent priapism.
Topics: Adolescent; Amines; Anemia, Sickle Cell; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2012 |
[Occipital neuralgia: clinical and therapeutic characteristics of a series of 14 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amines; Amitriptyline; Analgesics; Cyclohexanecarboxylic | 2013 |
Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer.
Topics: Aged; Amines; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2015 |
Gabapentin-induced myopathy in 2 patients on short daily hemodialysis.
Topics: Adult; Amines; Anticonvulsants; Atorvastatin; Calcium Channels; Comorbidity; Cyclohexanecarboxylic A | 2005 |
[The 10-minute-consultation: chronic singultus].
Topics: Aged; Amines; Anti-Ulcer Agents; Anticonvulsants; Chronic Disease; Cyclohexanecarboxylic Acids; Diag | 2007 |
Effects of gabapentin on cocaine self-administration, cocaine-triggered relapse and cocaine-enhanced nucleus accumbens dopamine in rats.
Topics: Amines; Animals; Anti-Anxiety Agents; Cocaine; Cocaine-Related Disorders; Cyclohexanecarboxylic Acid | 2008 |
Recurrent postoperative CRPS I in patients with abnormal preoperative sympathetic function.
Topics: Adult; Amines; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nerve Block; Carpal Tu | 2008 |
The use of gabapentin for recurrent painful attacks with multiple piloleiomyomas.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Humans; Leiomy | 2008 |
Rebound psychiatric and physical symptoms after gabapentin discontinuation.
Topics: Acetates; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Fluoxetin | 1998 |
Open maintenance treatment of bipolar disorder spectrum patients who responded to gabapentin augmentation in the acute phase of treatment.
Topics: Acetates; Acute Disease; Adult; Amines; Antimanic Agents; Bipolar Disorder; Cyclohexanecarboxylic Ac | 1999 |
Use of gabapentin in the treatment of childhood reflex sympathetic dystrophy.
Topics: Acetates; Amines; Child; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Excitatory A | 2000 |
Adjunctive gabapentin in treatment-resistant depression: a retrospective chart review.
Topics: Acetates; Adult; Amines; Anti-Anxiety Agents; Cyclohexanecarboxylic Acids; Depressive Disorder; Dose | 2001 |